Maravai LifeSciences Holdings Inc. (MRVI)
MRVI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1823239/000182323926000011/0001823239-26-000011-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MRVI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001823239 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $185.7M |
| Net income | -$130.8M |
| Operating income | -$215.3M |
| Net margin | -70.4% |
| Operating margin | -115.9% |
| Revenue growth | -28.3% |
| Cash | $216.9M |
| Total assets | $770.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 10.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $73.0M cash; operating cash flow -$1.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 259,938,547 (2026-10-29); 255,706,831 a year earlier. | Cover page 2026-10-29 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, San Diego, California, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-07-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $1.9M, sold $254K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $45.9M | -$13.8M | $5.0M | $73.0M | $147.2M | $213.0M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $51.4M | -$12.4M | $4.0M | $70.1M | $147.1M | $208.8M | 10-Q 2026-08-07 |
| Q1 2026 2026-03-31 | $65.8M | -$3.7M | $8.7M | $165.9M | $241.0M | $204.7M | 10-Q 2026-05-08 |
| Q4 2025 2025-12-31 | $49.9M | -$35.7M | -$22.8M | $216.9M | $291.8M | $185.7M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $41.6M | -$25.6M | -$15.2M | $243.6M | $292.8M | $192.4M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $47.4M | -$39.6M | -$10.3M | $269.9M | $293.9M | $219.8M | 10-Q 2026-08-07 |
| Q1 2025 2025-03-31 | $46.9M | -$29.9M | -$9.4M | $285.1M | $294.9M | $241.9M | 10-Q 2026-05-08 |
| Q4 2024 2024-12-31 | $56.6M | -$25.9M | -$14.6M | $322.4M | $295.9M | $259.2M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2021-09-13 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 426 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.3% |
| 1 month | +15.5% |
| 3 months | +30.4% |
| Year to date | +132.0% |
| 1 year | +132.0% |
| From 52-week high | -16.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| HRMY | Harmony Biosciences Holdings Inc. | $32.96 | -2.37% | $1.9B |
| VERA | Vera Therapeutics Inc. | $26.97 | -4.02% | $1.9B |
| TRVI | Trevi Therapeutics Inc. | $13.29 | -2.64% | $1.9B |
| ZBIO | Zenas BioPharma Inc. | $27.93 | -0.29% | $1.9B |
| TRAX | First Tracks Biotherapeutics Inc. Ordinary Shares | $46.56 | -1.15% | $2.0B |
| SEPN | Septerna Inc. | $41.67 | -2.18% | $2.0B |
| ETON | Eton Pharmaceuticals Inc. | $63.88 | -0.08% | $1.8B |
| ZYME | Zymeworks Inc. | $26.45 | +0.80% | $1.8B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier